Particular human papillomavirus (HPV) subtypes are implicated in the genesis of abnormal cervical cytology and cervical cancer. While most immunocompetent hosts clear HPV infection with no sequelae, some develop premalignant cytological changes of whom a minority subsequently progress to overt carcinoma. Immunocompromised patients, such as renal allograft recipients and HIV-infected individuals, have a higher rate of cytological abnormalities. This is thought to be due to prolonged persistence of virus due to impaired clearance by the immune system. We undertook a retrospective review of the cervical cytology of all women who underwent BMT at two transplant centres and who had cervical smears performed between 1990 and 1998. The rate of cytological abnormalities was significantly higher than in the general population before BMT (ageadjusted odds ratio (OR) 2.2, P = 0.02) and after BMT (OR 7.0, P Ͻ 0.0001). After BMT, allogeneic recipients had a higher rate of abnormalities than did autologous patients (OR 2.6, P = 0.02) although only allogeneic recipients had a higher rate of abnormalities post-BMT compared to pre-BMT (allogeneic OR 6.8, P = 0.004). These observations suggest that pre-transplant disease and treatment factors increase the risk of cytologic abnormalities and that transplant-related factors such as conditioning therapy and immunosuppression further increase this risk. These data suggest that more frequent screening may be required in these at-risk groups, especially allogeneic recipients. Prospective studies are required to further evaluate cytological abnormalities and HPV shedding in these populations. The highest prevalence of HPV-induced cervical cytological changes occurs in the early part of the third decade, 7 while the mean age of invasive carcinoma occurs in the middle of the sixth decade, 8 suggesting a prolonged latent phase of infection before the onset of overt malignant disease. This forms the basis of regular cytological screening, most commonly in the form of a Papanicolou (Pap) smear which detects cytological changes and allows intervention prior to the development of invasive disease.
infection by DNA hybridisation, 1 some studies have reported rates of up to 46% in at-risk populations when evaluated by very sensitive tests such as polymerase chain reaction (PCR). 2 HPV consists of over 80 genotypes with various subtypes showing differential tissue tropism and having associations with specific disease manifestations. Current evidence now strongly implicates HPV as a causative agent in cervical cancer, including epidemiological data from large casecontrol studies and the demonstration of HPV genomes in 93% of invasive cervical cancers. Two 'high risk' types, HPV-16 and HPV-18, are found in 40-60% and 10-20% of invasive cancers, respectively. [3] [4] [5] [6] The highest prevalence of HPV-induced cervical cytological changes occurs in the early part of the third decade, 7 while the mean age of invasive carcinoma occurs in the middle of the sixth decade, 8 suggesting a prolonged latent phase of infection before the onset of overt malignant disease. This forms the basis of regular cytological screening, most commonly in the form of a Papanicolou (Pap) smear which detects cytological changes and allows intervention prior to the development of invasive disease.
In the immunocompetent host, it has been demonstrated that infection is usually transient, with a reported median duration of 8 months. Seventy percent of women clear new infections within 12 months and 91% clear by 24 months, leading to frequent spontaneous resolution of early dysplastic changes. 9 Patients who are immunocompromised, however, present special problems, presumably due to an impaired ability to clear virus. Renal transplant recipients have been shown to have a significantly higher prevalence of both HPV infection and cervical, as well as anal dysplasia. [10] [11] [12] In HIV-infected women, HPV DNA is two to three times more frequently isolated from cervical specimens and almost 15 times more frequently from anal swabs compared with HIV-negative controls. HIV-infected women are also approximately five times more likely to develop squamous intraepithelial lesions and cervical cancer is now included in the list of AIDS-defining illnesses. In particular, it has been demonstrated that HIV-infected women develop a significantly higher incidence of persistent infection with high-risk HPV subtypes, which probably explains their susceptibility to dysplasia and carcinoma. 13 While these immunocompromised populations have been characterised, there is currently no published information on rates of cytological abnormalities in women who have undergone BMT, despite these patients being among the most severely immunocompromised of individuals and thus potentially at greatest risk. Moreover, it is not known whether chemotherapy or radiation therapy associated with the treatment of the underlying malignancy, or the malignancy itself may contribute directly to the risk of dysplasia.
There are no specific cervical cytological screening guidelines for BMT recipients. Accordingly, a retrospective review of cervical cytology results was conducted in female BMT recipients to evaluate the prevalence of cytological abnormalities in this patient group compared with the general population.
Materials and methods

Patients and data
This study evaluated all available Pap smears of women who underwent allogeneic or autologous BMT at two centres in Melbourne between June 1989 and June 1998. The Institutional Review Boards of both hospitals approved the protocol. The Victorian Cervical Cytology Registry was established in 1989 to maintain records of women undergoing Pap smears in the state of Victoria and served as the source for cytology results for both the general population, as well as for the BMT recipient data. Informed consent was obtained from all women who had undergone BMT and whose cytology results had been added to the registry from its inception. Cytological results from these patients were available from February 1990 to November 1998. Results of cytology grade were reported according to a modified Bethesda classification as follows: negative, lowgrade abnormality (including cervical intraepithelial neoplasia (CIN) I, non-specific change and changes associated with HPV infection), inconclusive, high grade and unsatisfactory specimen. 14 The registry also records the results of cervical biopsies performed on patients. Grading of epithelial abnormalities was recorded according to the Bethesda classification. 15 Reports were classified as CIN grades I, II or III depending on the depth of epithelial involvement. If the biopsy was normal, it was classified as benign and if it showed clear evidence of HPV cytopathic changes in the absence of dysplasia it was classified as HPV infection. Specimens considered unsatisfactory for adequate histological evaluation were classified as such.
Statistical analysis
The detection of one abnormal Pap smear usually results in more frequent subsequent smear sampling in that individual in order to monitor changes in cervical cytology. To ensure that the frequency of abnormal smears was not overestimated, the annual proportion of first abnormal Pap smear each year by 5-year age group was examined for the years 1990-1998. The proportion of abnormal Pap smears in women who underwent BMT, both pre-and post-transplant, was then compared with the proportion of abnormal smears amongst all women whose results were included on the Victorian Cervical Cytology Registry. In addition, the proportion of first abnormal smears post-BMT amongst women who underwent autologous BMT was compared with those who underwent allogeneic BMT.
There was a relatively small number of women who had undergone BMT during the years studied. Therefore, although data were extracted in 5-year age groups, adjustment for age and comparison with the registry population was done in only four age groups, 25-34 years, 35-39 years, 40-44 years and 45-69 years due to insufficient numbers in the other age groups. The proportion of abnormal smears in each of the four age groups was averaged over the 9 years studied. Age-adjusted odds ratios for each comparison were estimated by logistic regression using the statistical software package Stata (Stata Corporation, TX, USA).
There was a trend towards an increase in the proportion of abnormal smears with time in the total registry population. In order to make the most conservative comparison with the registry population, a reference population was constructed in which the year with the highest proportion of abnormal Pap smears was chosen as the year with which the averaged proportion of abnormal Pap smears in the study was compared. A different comparison year was chosen for each age group, if necessary, and the logistic regression was repeated using this constructed population.
Results
Seventy-six BMT recipients who were entered into the registry gave informed consent for the study. A total of 373 Pap smears from these patients was recorded in the registry between February 1990 and November 1998. Twelve women underwent only pre-BMT smears and were not included in the analysis. The remaining 64 women underwent a total of 347 smears of which 215 were post-BMT and 132 were pre-BMT. Twenty-one smears were not evaluable due to inconclusive results or unsatisfactory specimens. Forty autologous recipients underwent 186 evaluable smears, of which 87 were the first smear post-BMT per calendar year and 77 the first pre-BMT smear per calendar year. Twenty-four allogeneic recipients underwent 140 evaluable smears, of which 75 were the first smear post-BMT per calendar year and 37 were the first pre-BMT smear per calendar year. The results of all evaluable first annual Pap smears are shown in Table 1 .
Five out of 14 autologous recipients demonstrating low grade smears were CIN 1, while five were non-specific and four were changes associated with HPV, respectively. Fourteen out of the 28 allogeneic patients demonstrating a low grade smear were CIN 1, while nine were non-specific and five were associated with HPV, respectively.
The median age at the time of transplantation for autologous recipients was 43 years (range 22-66) compared to 39 years for allogeneic recipients (range 29-52). The median duration of cytological follow-up post-BMT was 31 months for autologous recipients (range 6-90) compared to 42 months for allogeneic recipients (range 4-105).
The proportion of first abnormal Pap smear by age group and transplant type, for pre-BMT, post-BMT and the Cytology Registry population, for the years 1990-1998, is shown in Table 2 . There was evidence of an increased prevalence of abnormal smears compared to the general population both prior to, as well as following BMT. Comparing the proportion of the first abnormal Pap smear prior to BMT with the Cytology Registry population, the ageadjusted odds ratio (OR), with 95% confidence interval was 2.2 (confidence intervals (CI) 1.1-4.2, P = 0.02). Comparison with the constructed reference population reduced the odds ratio to 2.1 (CI 1.1-4.0, P = 0.03). Post-BMT, the odds of having an abnormal Pap smear increased dramatically. The age-adjusted odds ratio, with 95% confidence interval, comparing the proportion of first abnormal Pap smear post-BMT with the Cytology Registry population was 7.0 (CI 4.8-10.2), P Ͻ 0.0001. There was no significant change when this comparison was made with the constructed reference population (age adjusted odds ration 6.6, CI 4.5-9.6, P Ͻ 0.0001).
Women who underwent allogeneic BMT demonstrated a higher proportion of abnormal smears post-BMT than did those who received an autologous BMT (OR 2.6, 95% CI 1.2-6.0, P = 0.02). There was no difference in the proportion of abnormal Pap smears in these two groups of women pre-BMT (OR 1.8, CI 0.4-8.1, P = 0.443). In addition, recipients of allogeneic BMT had a significantly higher rate of abnormality post-BMT compared to pre-BMT (OR 6.8, CI 1.8-25.2, P Ͻ 0.004), in contrast to recipients of autologous BMT who did not demonstrate an increase (OR 2.2, CI 0.8-6.2, P = 0.142).
Nine patients (five autologous and four allogeneic) underwent colposcopy and biopsy post-BMT. Among the autologous recipients, one patient each demonstrated a CIN 
Discussion
This is the first published series of cervical cytological abnormalities in women undergoing BMT, a population at high risk due to inherent immunosuppression associated with the procedure. These data suggest that this population suffers a higher rate of abnormality than the general population.
There was a significantly higher rate of abnormalities in the recipients of BMT even prior to transplantation compared to the control population. There are two potential explanations for this phenomenon. First, the immunosuppression associated with malignancy and/or chemotherapy may allow persistent HPV replication even in the absence of BMT. Alternatively, the chemotherapy for the underlying malignancy or a malignant tendency inherent in the patient may in itself lead to dysplasia in the absence of HPV infection. Which factors are operative is currently unclear and will require virological correlation for elucidation.
The overall prevalence of cytological abnormalities after BMT for both autologous and allogeneic recipients over the period studied, when compared with an age-matched control group, was seven-fold higher and achieved statistical significance despite small patient numbers. This increase in the prevalence of dysplasia is comparable to the prevalence of 12.7% in a 10-year study of renal transplant recipients compared with 2.5% in matched immunocompetent controls. 10 Despite the absence of formal guidelines, the screening frequency in this population of women was high. Although there are no published data, it is felt that women who are screened frequently are more likely to have trivial selflimiting abnormalities identified compared to women screened infrequently. The marked increase in frequency of abnormal smears, particularly in the allogeneic group and the known predisposition of other immunosuppressed populations suggests that more frequent sampling is unlikely to explain fully the high prevalence of abnormal smears in this study and that a true effect of immunosuppression was seen.
Allogeneic recipients suffered a significantly higher rate of abnormalities compared to autologous recipients. The median age of women who underwent autologous BMT was higher compared to those who underwent allogeneic BMT. Women who are younger are known to have a higher rate of cytological abnormalities, suggesting that the true discrepancy between allogeneic and autologous recipients may have been overestimated. The age-adjusted data have accounted for this. It is also known that duration of HPV infection is correlated with the incidence of abnormalities. The duration of follow-up after BMT was similar in both groups and was also not the likely explanation for the difference in cytological abnormalities. This increase is likely due to allogeneic recipients being more immunosuppressed than autologous recipients due to an ongoing requirement for immunosuppressive medication and/or GVHD, which is known to be independently immunosuppressive. 16 This increased risk in allogeneic recipients is also the likely explanation for the significantly higher rate of smears taken for this group compared to autologous recipients (data not shown). Indeed, the rate of smear abnormalities post-BMT compared to pre-BMT was only significant for the allogeneic group, suggesting that factors pre-BMT were mainly responsible for the higher rate of abnormalities in the autologous group and that the limited immunosuppression postautoBMT did not confer a significant additional risk.
Patient numbers were too small to draw conclusions about the duration of abnormal smears, although there was a trend to more prolonged cytological abnormalities in allogeneic recipients. All six autologous recipients with an abnormal smear had a single abnormality that resolved and did not recur. By contrast, allogeneic recipients demonstrated multiple abnormal smears that often persisted. Autologous BMT is associated with a relatively short and defined period of immunosuppression lasting approximately 6 months after which immune function largely returns to normal. 16 Allogeneic BMT, on the other hand, often results in ongoing immunosuppression, due to GVHD and the associated need for ongoing immunosuppression which may allow persistent HPV replication and may result in ongoing dysplasia.
In women who demonstrated cytological abnormalities post-BMT, there were 10 in whom pre-BMT smears were available, five allogeneic and five autologous. In both groups, three of five women demonstrated no abnormalities pre-BMT, suggesting that screening women prior to BMT is not likely to be a sensitive predictor of identifying women at risk of subsequent abnormalities and therefore highlighting the need for more intensive monitoring post-BMT. These new cytological abnormalities may have either been true new infections or reactivations of latent virus in the setting of immunosuppression as seen commonly with other viral infections such as varicella zoster virus in this setting. 17 The rate of high-grade abnormalities, CIN II and III lesions and carcinoma was low for both groups and comparable to the normal population and control groups. This may partly be due to the small numbers in this study. It is also known, however, that the development of premalignant change requires prolonged and persistent infection. While the relatively short duration of immunosuppression in the autologous group makes it unlikely that these patients would develop significantly more high grade lesions than the normal population, the longer term immunosuppression in allogeneic recipients makes them more likely to do so as is seen in HIV infection. 13 The relatively short followup in the allogeneic patients, who demonstrate a tendency to persistent change, suggests that this group may be at risk for higher grade abnormalities and even carcinoma with longer follow-up and mandates the need for a long-term follow-up study in this group.
There are three unique features of BMT that may impact on cytological abnormalities independently of HPV infection. First, patients are subjected to intensive conditioning therapy and it is possible that the agents used in conditioning may result directly in cytological abnormalities. Second, these patients have malignancies for which the BMT is performed. Any underlying predisposition to malignancy may also impact on the incidence of cytological abnormalities. Finally, GVHD is known to result in mucosal lesions which may also involve genital tissues and potentially result in dysplasia due to involvement of the cervical epithelium. 17, 18 These factors may act either independently of HPV infection or synergistically with it to produce abnormal cytology. The small numbers of patients in this study did not allow for the adequate evaluation of the association of GVHD, conditioning regimen or underlying disease with abnormal cytology, although no trends were apparent (data not shown). These factors are being addressed currently in a larger prospective study.
At present there are no specific guidelines for female BMT recipients with respect to the frequency of Pap smear screening despite existing guidelines being in place for other immunosuppressed populations. 18 The policy for BMT recipients attending the centres in this study had been to perform cytological assessments at 2-yearly intervals as recommended for immunocompetent women. This study suggests that BMT patients, especially allogeneic recipients, are at increased risk of cervical dysplasia and that formal guidelines should be established for cytological examinations in this population. Although such patients need careful screening, it is not yet clear that screening needs to be more frequent as this would require as yet unavailable evidence that cervical lesions develop more rapidly.
In summary, this is the first study to document that women undergoing BMT, particularly allogeneic BMT, suffer a higher rate of cytological abnormalities than the general population. The particularly high rate in allogeneic BMT recipients, as well as the persistence of changes and ongoing immunosuppression suggests that this group may be at increased risk of progression to invasive carcinoma.
